

Regimen Reference Order – GYNE – methotrexate + DACTINomycin

ARIA: GYNE – [MD]

Planned Course: Every 14 days until normalization of β -HCG

Indication for Use: Gestational Trophoblastic Disease

CVAD: Preferred (VESICANT INVOLVED)

Proceed with treatment if:

Cycle 1

ANC equal to or greater than $1.5 \times 10^9/L$ AND Platelets equal to or greater than $100 \times 10^9/L$

Cycle 2 and onwards

ANC equal to or greater than $1.2 \times 10^9/L$ AND Platelets equal to or greater than $75 \times 10^9/L$

❖ Contact Physician if parameters not met

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – GYNE – methotrexate + DACTINomycin

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
Cycle 1 and all uneven cycles		
methotrexate	30 mg	IV Push over 3 minutes on Days 1 to 5
Cycle 2 and all even cycles		
dexamethasone	12 mg	Orally 30 minutes prior to DACTINomycin on Days 1 to 5
ondansetron	16 mg	Orally 30 minutes prior to DACTINomycin on Days 1 to 5
DACTINomycin	0.5 mg	IV Push over 5 minutes on Days 1 to 5 <i>*Nursing Alert: peripheral IV should be re-sited daily</i>

Flush after each medication:

- 50 mL over 6 minutes (500 mL/hr)

In the event of an infusion-related hypersensitivity reaction, refer to the ‘Hypersensitivity Reaction Standing Order’

REQUIRED MONITORING

Each cycle

- CBC, serum creatinine and liver enzymes as per Physician Orders
- serum β -HCG

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
Cycle 1 and all uneven cycles (methotrexate)		
None required		
Cycle 2 and all even cycles (DACTINomycin)		
dexamethasone	8 mg	Orally once daily on Days 6 and 7
metoclopramide	10-20 mg	Orally every 4 hours as needed for nausea and vomiting

DISCHARGE INSTRUCTIONS

- Instruct patient to continue taking anti-emetic(s) at home
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- Treatment continues for 2 cycles past normal quantitative β -HCG for low risk disease patients